Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 8153024, 10 pages
https://doi.org/10.1155/2017/8153024
Review Article

Potential Biological Markers of Atrial Fibrillation: A Chance to Prevent Cryptogenic Stroke

1Department of Neurology, Clinical Centre, University of Debrecen, Debrecen, Hungary
2Department of Neurology, Clinical Centre, University of Pécs, Pécs, Hungary
3Department of Cardiology, Clinical Centre, University of Debrecen, Debrecen, Hungary

Correspondence should be addressed to László Csiba; uh.bedinu.dem@abisc

Received 24 February 2017; Revised 15 May 2017; Accepted 4 June 2017; Published 13 July 2017

Academic Editor: Raffaele Serra

Copyright © 2017 István Szegedi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. A. Wolf, R. D. Abbott, and W. B. Kannel, “Atrial fibrillation as an independent risk factor for stroke: the Framingham study,” Stroke, vol. 22, no. 8, pp. 983–988, 1991. View at Publisher · View at Google Scholar · View at Scopus
  2. H. P. Adams Jr., B. H. Bendixen, L. J. Kappelle et al., “Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial,” Stroke, vol. 24, no. 1, pp. 35–41, 1993. View at Publisher · View at Google Scholar · View at Scopus
  3. H. J. Lin, P. A. Wolf, M. Kelly-Hayes et al., “Stroke severity in atrial fibrillation: the framingham study,” Stroke, vol. 27, no. 10, pp. 1760–1764, 1996. View at Publisher · View at Google Scholar · View at Scopus
  4. V. Fuster, L. E. Ryden, D. S. Cannom, and et al, “ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the american college of cardiology/american heart association task force on practice guidelines and the european society of cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the european heart rhythm association and the heart rhythm society,” Circulation, vol. 114, no. 7, pp. e257–e354, 2006. View at Publisher · View at Google Scholar
  5. T. Watson, E. Shantsila, and G. Y. Lip, “Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited,” The Lancet, vol. 373, no. 9658, pp. 155–166, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Friberg, N. Hammar, and M. Rosenqvist, “Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation,” European Heart Journal, vol. 31, no. 8, pp. 967–975, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Manina, G. Agnelli, C. Becattini, G. Zingarini, and M. Paciaroni, “96 hours ECG monitoring for patients with ischemic cryptogenic stroke or transient ischaemic attack,” Internal and Emergency Medicine, vol. 9, no. 1, pp. 65–67, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Kamel, B. B. Navi, L. Elijovich et al., “Pilot randomized trial of outpatient cardiac monitoring after cryptogenic stroke,” Stroke, vol. 44, no. 2, pp. 528–530, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. E. J. Hertervig, S. Yuan, J. Carlson, O. Kongstad-Rasmussen, and S. B. Olsson, “Evidence for electrical remodelling of the atrial myocardium in patients with atrial fibrillation. A study using the monophasic action potential recording technique,” Clinical Physiology and Functional Imaging, vol. 22, no. 1, pp. 8–12, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Kostin, G. Klein, Z. Szalay, S. Hein, E. P. Bauer, and J. Schaper, “Structural correlate of atrial fibrillation in human patients,” Cardiovascular Research, vol. 54, no. 2, pp. 361–379, 200. View at Google Scholar
  11. G. M. Marcus, L. M. Smith, K. Ordovas et al., “Intracardiac and extracardiac markers of inflammation during atrial fibrillation,” Heart Rhythm, vol. 7, no. 2, pp. 149–154, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Garlanda, B. Bottazzi, A. Bastone, and A. Mantovani, “Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility,” Annual Review of Immunology, vol. 23, pp. 337–366, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Masson, A. Aleksova, C. Favero et al., “Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: Data from the GISSI atrial fibrillation trial,” Heart, vol. 96, no. 23, pp. 1909–1914, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Gökhan, A. Ozhasenekler, H. Mansur Durgun, E. Akil, M. Üstundag, and M. Orak, “Neutrophil lymphocyte ratios in stroke subtypes and transient ischemic attack,” European Review for Medical and Pharmacological Sciences, vol. 17, pp. 653–657, 2013. View at Google Scholar
  15. L. Zhao, Q. Dai, X. Chen et al., “Neutrophil-to-lymphocyte ratio predicts length of stay and acute hospital cost in patients with acute ischemic stroke,” Journal of Stroke and Cerebrovascular Diseases, vol. 25, no. 4, pp. 739–744, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Ertaş, O. Sönmez, M. Turfan et al., “Neutrophil/lymphocyte ratio is associated with thromboembolic stroke in patients with non-valvular atrial fibrillation,” Journal of the Neurological Sciences, vol. 324, no. 1-2, pp. 49–52, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. W. Saliba, O. Barnett-Griness, M. Elias, and G. Rennert, “Neutrophil to lymphocyte ratio and risk of a first episode of stroke in patients with atrial fibrillation: a cohort study,” Journal of Thrombosis and Haemostasis, vol. 13, no. 11, pp. 1971–1979, 2015. View at Publisher · View at Google Scholar
  18. R. A. De Boer, L. Yu, and D. J. Van Veldhuisen, “Galectin-3 in cardiac remodeling and heart failure,” Current Heart Failure Reports, vol. 7, no. 1, pp. 1–8, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. J. E. Ho, X. Yin, D. Levy et al., “Galectin 3 and incident atrial fibrillation in the community,” American Heart Journal, vol. 167, no. 5, pp. 729–e1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Alonso, B. P. Krijthe, T. Aspelund et al., “Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium,” Journal of the American Heart Association, vol. 2, no. 2, Article ID e000102, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. K. M. Gurses, M. U. Yalcin, D. Kocyigit et al., “Effects of persistent atrial fibrillation on serum galectin-3 levels,” American Journal of Cardiology, vol. 115, no. 5, pp. 647–651, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. M. U. Yalcin, K. M. Gurses, D. Kocyigit et al., “The association of serum galectin-3 levels with atrial electrical and structural remodeling,” Journal of Cardiovascular Electrophysiology, vol. 26, no. 6, pp. 635–640, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Agrotis, N. Kalinina, and A. Bobik, “Transforming growth factor-β, cell signaling and cardiovascular disorders,” Current Vascular Pharmacology, vol. 3, no. 1, pp. 55–61, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Nakajima, H. O. Nakajima, O. Salcher et al., “Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-β1 transgene in the heart,” Circulation Research, vol. 86, no. 5, pp. 571–579, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Verheule, T. Sat, T. Everett IV et al., “Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-β1,” Circulation Research, vol. 94, no. 11, pp. 1458–1465, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. X. Lin, N. Wu, Y. Shi et al., “Association between transforming growth factor β1 and atrial fibrillation in essential hypertensive patients,” Clinical and Experimental Hypertension, vol. 37, no. 1, pp. 82–87, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. P. E. Van Den Steen, B. Dubois, I. Nelissen, P. M. Rudd, R. A. Dwek, and G. Opdenakker, “Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9),” Critical Reviews in Biochemistry and Molecular Biology, vol. 37, no. 6, pp. 375–536, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Li, G. Yang, B. Xie, K. Babu, and C. Huang, “Changes in matrix metalloproteinase-9 levels during progression of atrial fibrillation,” Journal of International Medical Research, vol. 42, no. 1, pp. 224–230, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. T. A. Zimmers, X. Jin, E. C. Hsiao, S. A. McGrath, A. F. Esquela, and L. G. Koniaris, “Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury,” Shock, vol. 23, no. 6, pp. 543–548, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. Q. Shao, H. Liu, C. Y. Ng et al., “Circulating serum levels of growth differentiation factor-15 and neuregulin-1 in patients with paroxysmal non-valvular atrial fibrillation,” International Journal of Cardiology, vol. 172, no. 2, pp. e311–e31, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. O. Odiete, M. F. Hill, and D. B. Sawyer, “Neuregulin in cardiovascular development and disease,” Circulation Research, vol. 111, no. 10, pp. 1376–1385, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. O. Sonmez, F. U. Ertem, M. A. Vatankulu et al., “Novel fibro-inflammation markers in assessing left atrial remodeling in non-valvular atrial fibrillation,” Medical Science Monitor, vol. 20, pp. 463–470, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. K. M. Choi, J. S. Lee, E. J. Kim et al., “Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease,” European Journal of Endocrinology, vol. 158, no. 2, pp. 203–207, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. L. T. Jensen, “The aminoterminal propeptide of type III procollagen. Studies on physiology and pathophysiology,” Danish Medical Bulletin, vol. 44, no. 1, pp. 70–78, 1997. View at Google Scholar
  35. M. A. Rosenberg, M. Maziarz, A. Y. Tan et al., “Circulating fibrosis biomarkers and risk of atrial fibrillation: The Cardiovascular Health Study (CHS),” American Heart Journal, vol. 167, no. 5, pp. 723–e2, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. L. B. Daniels and A. S. Maisel, “Natriuretic peptides,” Journal of the American College of Cardiology, vol. 50, no. 25, pp. 2357–2368, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Silvet, Y. Young-Xu, D. Walleigh, and S. Ravid, “Brain natriuretic peptide is elevated in outpatients with atrial fibrillation,” American Journal of Cardiology, vol. 92, no. 9, pp. 1124–1127, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Naya, K. Yukiiri, N. Hosomi et al., “Brain natriuretic peptide as a surrogate marker for cardioembolic stroke with paroxysmal atrial fibrillation,” Cerebrovascular Diseases, vol. 26, no. 4, pp. 434–440, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. K. K. Patton, P. T. Ellinor, S. R. Heckbert et al., “N-Terminal pro-b-type natriuretic peptide is a major predictor of the development of atrial fibrillation: The cardiovascular health study,” Circulation, vol. 120, no. 18, pp. 1768–1774, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. K. K. Patton, S. R. Heckbert, A. Alonso et al., “N-terminal pro-B-type natriuretic peptide as a predictor of incident atrial fibrillation in the Multi-Ethnic study of atherosclerosis: The effects of age,sex and ethnicity,” Heart, vol. 99, no. 24, pp. 1832–1836, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Kara, M. H. Geisel, and S. Möhlenkamp, “B-type natriuretic peptide for incident atrial fibrillation-The Heinz Nixdorf Recall Study,” Journal of Cardiology, vol. 65, no. 6, pp. 453–458, 2014. View at Publisher · View at Google Scholar
  42. M. Rodríguez-Yáñez, S. Arias-Rivas, M. Santamaría-Cadavid, T. Sobrino, J. Castillo, and M. Blanco, “High pro-BNP levels predict the occurrence of atrial fibrillation after cryptogenic stroke,” Neurology, vol. 81, no. 5, pp. 444–447, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Suissa, S. Bresch, S. Lachaud, and M. H. Mahagne, “Brain natriuretic peptide: a relevant marker to rule out delayed atrial fibrillation in stroke patient,” Journal of Stroke and Cerebrovascular Diseases, vol. 22, no. 7, pp. e103–e110, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. K.-I. Miyamoto, M. Ito, M. Kuwahata, S. Kato, and H. Segawa, “Inhibition of intestinal sodium-dependent inorganic phosphate transport by fibroblast growth factor 23,” Therapeutic Apheresis and Dialysis, vol. 9, no. 4, pp. 331–335, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Baum, S. Schiavi, V. Dwarakanath, and R. Quigley, “Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules,” Kidney International, vol. 68, no. 3, pp. 1148–1153, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. J. S. Mathew, M. C. Sachs, R. Katz et al., “Fibroblast growth factor-23 and incident atrial fibrillation: The multi-ethnic study of atherosclerosis (MESA) and the cardiovascular health study (CHS),” Circulation, vol. 130, no. 4, pp. 298–307, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Diamant, M. E. Tushuizen, A. Sturk, and R. Nieuwland, “Cellular microparticles: New players in the field of vascular disease?” European Journal of Clinical Investigation, vol. 34, no. 6, pp. 392–401, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Choudhury, I. Chung, A. D. Blann, and G. Y. H. Lip, “Elevated platelet microparticle levels in nonvalvular atrial fibrillation: Relationship to P-selectin and antithrombotic therapy,” Chest, vol. 131, no. 3, pp. 809–815, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Ederhy, E. Di Angelantonio, Z. Mallat et al., “Levels of Circulating Procoagulant Microparticles in Nonvalvular Atrial Fibrillation,” American Journal of Cardiology, vol. 100, no. 6, pp. 989–994, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. P. Vallence, A. Leone, A. Calver, J. Collier, and S. Moncada, “Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis,” Journal of Cardiovascular Pharmacology, vol. 20, no. 12, pp. S60–S62, 1992. View at Publisher · View at Google Scholar
  51. A. Cengel, A. Sahinarslan, G. Biberoǧlu et al., “Asymmetrical dimethylarginine level in atrial fibrillation,” Acta Cardiologica, vol. 63, no. 1, pp. 33–37, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. Z. Liu, C. Zhou, Y. Liu et al., “The expression levels of plasma microRNAs in atrial fibrillation patients,” PLoS ONE, vol. 7, no. 9, Article ID e44906, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. D. D. McManus, H. Lin, K. Tanriverdi et al., “Relations between circulating microRNAs and atrial fibrillation: data from the Framingham Offspring Study,” Heart Rhythm, vol. 11, no. 4, pp. 663–669, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. Y. Lu, Y. Zhang, N. Wang et al., “MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation,” Circulation, vol. 122, pp. 2378–2387, 2010. View at Google Scholar